Retina Implant AG
Retina Implant AG — a developer of subretinal implants for patients blinded by retinitis pigmentosa (RP) — announced earlier this week it had received CE approval of its Alpha AMS device for marketing in the European economic area.
The Alpha AMS is the next generation of the Alpha IMS (CE marked in 2013) and is designed to restore some useful vision in patients blinded by RP. It has been in clinical trials in Germany and the UK since 2014. The technology has an increased number of pixels (1,600), reportedly giving it the most electrodes of any neuroprosthetic implant on the market and is estimated to last several years in the body.
Click here to read the full press release.